Overview

A First-in-human of Multiplle Doses of BB-1701 in Subjects With Locally Advanced/Metastatic Solid Tumors

Status:
Not yet recruiting
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
The study consists of two phases: dose-escalation (Phase I) and cohort expansion (Phase II).
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Bliss Biopharmaceutical (Hangzhou) Co., Ltd